Biotherapeutics

Biotherapeutics is the fastest rising part of the pharmaceuticals and possess that ability to mark individual molecules in the human body. It is also known as biotech drugs. This subject is the only one under biotechnology related to pharmaceuticals or medicine. It is the production of drugs from living organisms, and it is therapeutic because it seeks power from living cells to make or alter protein products to create therapies.

Biotherapeutics is distinct because it involves complex processes and formulation for a particular function using the most effective cell line. It also requires modern production tools and procedures to ensure safety, security and efficiency.

Biotherapeutics is a force to reckon with in the history of biotechnology, having insulin as its first innovation of biotechnology. The industry has been in existence for over thirty years, and we have consistently put out products that treat complicated illnesses such as cancer, arthritis, anaemia and heart disease.

Unlike other probiotics discoveries, therapeutic medicines’ research development process is strenuous and complicated with high risk. Hence, to compensate researchers, there must be an IP system to protect their interests.

Today, the formulation of biotherapeutics has changed due to the emergence of DNA technology. Products are produced, standardised and packaged. Hence, they originated from recombinant DNA technology (which are interleukin, interferon and growth factors).

Nonetheless, the rise in costs of raw materials and organic ingredients influences sustainable biotherapeutics products. The increasing rate of pricing affects the Australian government as well as patients who depend on reliable, timely and affordable access to frequently used medicines.

Given this, Firn M collaborates with one of the largest probiotic companies globally to investigate the continuous increase in drugs pricing and discover new ways to minimise the costs without compromising quality. We also aim at increasing supply and promoting innovations for the benefit of society in general, the industry and the government.

Apart from conducting researches at Firn M, we also undergo and supervise specific projects, which include:

• The use of microbial platforms for discovering the characterisation of new inoculants development of buyers
• Identification of new active principles
• The explanation of physiological processes that could reveal new targets for the design

We assist the biotechnology and genetic engineering group created by the Queensland government. Also, it is pertinent to know that while we run trials majorly in Australia, we also partner with overseas facilities for further research or discoveries.

It is expedient to know that research involves finding an organism in the right condition and under good manufacturing condition in the development of biotherapeutics drugs. It is because a little alteration in the manufacturing process can lead to a different final result. A researcher should create a specific and defined environment for such activity. Therefore, we are diligent and compliant with all instructions and regulations to achieve the correct quality and efficacy.

Finally, we hope to evolve from human therapeutics to animal therapeutics that apply all animal species dynamics.